Aktienanalyse zu Rezolute Inc (RZLT)RZLTRezolute Inc

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rezolute Inc (RZLT) appears to be a good buy right now, trading at $3.58, which is significantly below analyst price targets of $12 and $15, suggesting potential upside of 235% to 319%. The stock has a low RSI of 21.81, indicating it is oversold, which could lead to a rebound. However, the company has reported consistent losses, with a net income of -$20,491,000 in the last quarter, posing a risk to investors.